STOCK TITAN

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags
Vincerx Pharma (OTC Pink: VINC) announced the adjournment of its Special Meeting of Stockholders to July 16, 2025, seeking additional time to secure votes for the company's Dissolution Proposal. The board unanimously recommends stockholders vote FOR the proposal, emphasizing that delays will increase operating costs and potentially eliminate any remaining funds for stockholder distributions. Acting CEO Dr. Raquel Izumi stressed the importance of approving the dissolution to maximize the possibility of shareholders receiving some value for their shares. The company has provided multiple voting methods including phone and internet options. If approved, U.S. stockholders may be eligible for capital loss tax benefits if distributions are less than their tax basis.
Vincerx Pharma (OTC Pink: VINC) ha annunciato il rinvio della sua Assemblea Speciale degli Azionisti al 16 luglio 2025, per ottenere più tempo per raccogliere voti a favore della Proposta di Scioglimento della società. Il consiglio di amministrazione raccomanda all'unanimità agli azionisti di votare SÌ alla proposta, sottolineando che ulteriori ritardi aumenterebbero i costi operativi e potrebbero azzerare i fondi residui destinati alle distribuzioni agli azionisti. L'Amministratore Delegato ad interim, la Dott.ssa Raquel Izumi, ha evidenziato l'importanza di approvare lo scioglimento per massimizzare la possibilità che gli azionisti ottengano un valore dalle loro azioni. La società ha messo a disposizione diversi metodi di voto, inclusi telefono e internet. Se approvata, gli azionisti statunitensi potrebbero beneficiare di vantaggi fiscali per perdite in conto capitale nel caso in cui le distribuzioni siano inferiori al loro costo fiscale.
Vincerx Pharma (OTC Pink: VINC) anunció el aplazamiento de su Reunión Especial de Accionistas hasta el 16 de julio de 2025, buscando más tiempo para asegurar votos a favor de la Propuesta de Disolución de la empresa. La junta directiva recomienda unánimemente que los accionistas voten a FAVOR de la propuesta, destacando que los retrasos aumentarán los costos operativos y podrían eliminar los fondos restantes para distribuciones a los accionistas. La directora ejecutiva interina, la Dra. Raquel Izumi, enfatizó la importancia de aprobar la disolución para maximizar la posibilidad de que los accionistas reciban algún valor por sus acciones. La compañía ha ofrecido múltiples métodos de votación, incluyendo opciones telefónicas e internet. Si se aprueba, los accionistas estadounidenses podrían ser elegibles para beneficios fiscales por pérdidas de capital si las distribuciones son menores que su base fiscal.
Vincerx Pharma(OTC Pink: VINC)는 회사 해산 제안에 대한 투표 확보를 위해 추가 시간이 필요함에 따라 주주 특별총회를 2025년 7월 16일로 연기했다고 발표했습니다. 이사회는 만장일치로 주주들이 제안에 찬성 투표할 것을 권고하며, 지연 시 운영 비용이 증가하고 주주 배분을 위한 잔여 자금이 사라질 수 있음을 강조했습니다. 임시 CEO인 라켈 이즈미 박사는 주주들이 보유 주식에 대해 어느 정도 가치를 받을 수 있도록 해산 승인의 중요성을 강조했습니다. 회사는 전화 및 인터넷 등 다양한 투표 방법을 제공하고 있습니다. 승인될 경우, 미국 주주들은 배분금이 세금 기준액보다 적을 경우 자본 손실 세제 혜택을 받을 수 있습니다.
Vincerx Pharma (OTC Pink : VINC) a annoncé le report de son Assemblée Générale Extraordinaire des actionnaires au 16 juillet 2025, afin d'obtenir plus de temps pour recueillir des votes en faveur de la proposition de dissolution de la société. Le conseil d'administration recommande à l'unanimité aux actionnaires de voter POUR cette proposition, soulignant que tout retard augmenterait les coûts d'exploitation et pourrait épuiser les fonds restants destinés aux distributions aux actionnaires. La PDG par intérim, le Dr Raquel Izumi, a insisté sur l'importance d'approuver la dissolution pour maximiser les chances que les actionnaires obtiennent une certaine valeur pour leurs actions. La société a mis à disposition plusieurs méthodes de vote, y compris par téléphone et internet. En cas d'approbation, les actionnaires américains pourraient bénéficier d'avantages fiscaux en cas de pertes en capital si les distributions sont inférieures à leur base fiscale.
Vincerx Pharma (OTC Pink: VINC) hat die Verschiebung seiner außerordentlichen Hauptversammlung der Aktionäre auf den 16. Juli 2025 bekanntgegeben, um mehr Zeit zu gewinnen, Stimmen für den Auflösungsantrag des Unternehmens zu sichern. Der Vorstand empfiehlt einstimmig, dass die Aktionäre FÜR den Antrag stimmen, da Verzögerungen die Betriebskosten erhöhen und möglicherweise verbleibende Mittel für Ausschüttungen an die Aktionäre aufbrauchen würden. Die amtierende CEO Dr. Raquel Izumi betonte die Bedeutung der Genehmigung der Auflösung, um die Chance zu maximieren, dass Aktionäre einen Wert für ihre Aktien erhalten. Das Unternehmen bietet mehrere Abstimmungsmöglichkeiten, darunter Telefon- und Internetoptionen. Bei Genehmigung könnten US-Aktionäre steuerliche Vorteile bei Kapitalverlusten erhalten, falls die Ausschüttungen unter ihrem steuerlichen Einstandswert liegen.
Positive
  • Potential for remaining cash distributions to stockholders if dissolution is approved quickly
  • U.S. stockholders may be eligible for capital loss tax benefits
  • Multiple convenient voting methods provided for stockholders
Negative
  • Company is seeking dissolution and winding down of operations
  • Continued delays reduce or may eliminate funds available for stockholder distributions
  • Risk of potential bankruptcy if dissolution is not approved
  • Ongoing public company costs and operating expenses continue to deplete remaining funds

Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders

SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC Pink: VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the “Dissolution Proposal”), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal.

Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal.

Vincerx’s board of directors unanimously recommends that stockholders vote FOR the Dissolution Proposal and believes that approval of the Dissolution Proposal is extremely important to stockholders for a number of reasons, including the following:

  • Preserve Possibility of Distributions. Vincerx is hopeful that cash will be available for distribution to its stockholders. However, further delays in approving the Dissolution Proposal will result in continued public company and other operating costs and expenses - reducing or eliminating what funds could remain for distribution to stockholders. Approving the Dissolution Proposal will allow Vincerx to move forward expeditiously and maximize the likelihood of a distribution to its stockholders.
  • Recognize Potential Tax Benefits. U.S. stockholders who receive less than their tax basis in their shares could be eligible to recognize a capital loss for U.S. federal income tax purposes. Timely approval of the Dissolution Proposal will facilitate this recognition.

“We believe it is extremely important that our stockholders vote FOR the Dissolution Proposal,” said Dr. Raquel Izumi, Acting CEO. “We understand the disappointment that all of us who are stockholders and supported the company over the years feel, but approving the Dissolution Proposal at least gives stockholders the possibility of receiving some value for their shares. Delaying approval of the Dissolution Proposal will simply result in the company continuing to incur ongoing operating costs and expenses, which will only reduce or even eliminate the likelihood that there will be any amounts left for distribution to stockholders. We therefore urge all stockholders to vote FOR the Dissolution Proposal before the reconvened meeting on July 16, 2025.”

Every vote matters. Stockholders must ACTIVELY VOTE for their vote to count. Any delay in approving the Dissolution Proposal will result in increased expenditures and reduce the likelihood that amounts will be available for distribution to stockholders.

Voting is quick and simple:

  • BY PHONE: Please call Advantage Proxy, Vincerx’s proxy solicitor, toll-free at 1-877-870-8565 between the hours of 9:00 a.m. and 9:00 p.m., Eastern Time, Monday through Friday. You can also contact Advantage Proxy if you have any questions about voting.
  • BY INTERNET: Vote by going to www.proxyvote.com and entering the control number on your proxy card or by following the instructions provided by your broker, bank, or other nominee.

Your vote FOR the Dissolution Proposal is very important - please VOTE TODAY.

Additional Information

Information regarding the Dissolution Proposal, including the board of director’s reasons for recommending approval of the Dissolution Proposal, is set forth in the company’s proxy statement and supplements thereto, which have been filed with the Securities and Exchange Commission (“SEC”) and are available at the SEC’s website at www.sec.gov.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the federal securities laws including, but not limited to, statements about the reasons for approving, and the consequences of failing to approve, the Dissolution Proposal; the potential availability of amounts for distribution to stockholders; and the potential tax benefits to stockholders of approving the Dissolution Proposal. Forward-looking statements involve risks and uncertainties that may cause actual results or performance to differ materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks involved in dissolving, liquidating, and winding down Vincerx’s business and affairs; the timing or amount of distributions, if any, to Vincerx’s stockholders; stockholder approval of the Dissolution Proposal and the timeliness of such approval; the risk that Vincerx may need to seek protection of the bankruptcy court; and the other factors discussed in Vincerx’s reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to Vincerx as of the date of this press release. Vincerx undertakes no duty or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information:

info@vincerx.com


FAQ

What is the purpose of Vincerx Pharma's (VINC) Special Meeting adjournment to July 16, 2025?

The meeting was adjourned to allow more time to solicit votes needed to approve the Dissolution Proposal, which would liquidate and dissolve the company.

What happens if VINC stockholders don't approve the Dissolution Proposal?

Failure to approve will result in continued operating costs that could reduce or eliminate potential distributions to stockholders, and the company may need to seek bankruptcy protection.

What are the potential benefits for VINC shareholders if the Dissolution Proposal is approved?

Shareholders may receive cash distributions from remaining funds and U.S. stockholders could be eligible for capital loss tax benefits if distributions are less than their tax basis.

How can VINC stockholders vote on the Dissolution Proposal?

Stockholders can vote by phone through Advantage Proxy at 1-877-870-8565 or online at www.proxyvote.com using their control number.

When is the deadline for VINC stockholders to vote on the Dissolution Proposal?

Stockholders must vote before the reconvened meeting on July 16, 2025, at 10:00 a.m. Pacific time.
Vincerx Pharma Inc

OTC:VINC

VINC Rankings

VINC Latest News

VINC Stock Data

3.54M
5.02M
11.59%
10.77%
8.57%
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO